Can a new treatment delay prostate cancer from spreading further?

For men facing oligometastatic prostate cancer, a new treatment called lutetium vipivotide tetraxetan is being tested to see if it can help. This study aims to find out if this drug can effectively delay the progression of cancer after initial treatment. Participants will undergo thorough assessments, including scans to evaluate their cancer. Those in the study will receive either the new drug or standard observation. All participants will also receive targeted radiation therapy to treat their cancer spots. The goal is to see if the new treatment can extend the time before the cancer spreads, which is crucial for maintaining a better quality of life. With 450 participants expected, the results could provide valuable insights into managing early-stage prostate cancer and potentially reduce the need for more intense treatments like hormone therapy.